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Abstract
We analyzed the clinical response and the time to relapse after
discontinuation of continuous long-term infliximab therapy in
patients with ankylosing spondylitis (AS). After 3 years of
infliximab therapy, all AS patients (n = 42) discontinued
treatment (time point (TP)1) and were visited regularly for 1 year
in order to assess the time to relapse (TP2). Relapse was
defined as an increase to a value ≥ 4 on the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) and a physician's
global assessment ≥ 4 according to the recommendations of the
Assessments in Ankylosing Spondylitis (ASAS) working group.
After 52 weeks, 41 of the 42 patients (97.6%) had to be
reinfused because of relapse. The mean change in the BASDAI
between TP1 and TP2 was 3.6 ± 1.7 and that in the physician's
global assessment was 4.4 ± 1.8 (both P < 0.001). The mean
time to relapse was 17.5 weeks (± 7.9 weeks, range 7 to 45).
Ten patients (24%) showed a relapse within 12 weeks and 38
patients (90.5%), within 36 weeks. After 52 weeks, only one
patient had remained in ongoing remission without further
treatment with anti-tumor-necrosis factor. Patients who were in
partial remission according to the ASAS criteria and those with
normal C-reactive protein levels at the time point of withdrawal
had longer times to relapse after discontinuation of the
treatment. Retreatment with infliximab was safe and resulted in
clinical improvement in all patients to a state similar to that
before the treatment was stopped. Discontinuation of long-term
therapy with infliximab eventually led to relapse of disease
activity in all patients but one.
Introduction
Ankylosing spondylitis (AS) is a chronic, immune-mediated
inflammatory disease that is associated with inflammation
in the sacroiliac joints, the axial skeleton, entheses, periph-
eral joints, the uvea, and other structures [1-3]. In rand-
omized clinical trials, agents targeting the proinflammatory
cytokine tumor necrosis factor (TNF)-α, such as the mono-
clonal antibody infliximab, have produced significant
improvement of signs and symptoms in AS patients [4].
Persistence of clinical response was reported in long-term
follow-up studies over 2 [5] and 3 years [6]. These results
have been substantiated in studies using magnetic reso-
nance imaging of the spine [7].
We reasoned that it was unclear whether after 3 years of
successful therapy with infliximab our patients still needed
treatment. Similarly, it was unknown whether discontinua-
tion of the infliximab would be tolerated and whether a
restart would be efficacious and safe. Furthermore, nothing
was known about the clinical parameters predictive of flare
after discontinuation of infliximab therapy. Therefore, we
decided to study these questions in our cohort, who had
been treated with infliximab for the preceding 3 years [6].R439
AS = ankylosing spondylitis; ASAS = Assessments in Ankylosing Spondylitis [working group]; BASDAI = Bath Ankylosing Spondylitis Disease Activ-
ity Index; BASFI = Bath Ankylosing Spondylitis Function Index; BASMI = Bath AS Metrology Index; CI = confidence interval; CRP = C-reactive pro-
tein; ESR = erythrocyte sedimentation rate; NRS-P = numerical rating scale for pain; TNF = tumor necrosis factor; TP = time point; TtR = time to 
relapse.
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Patients and study protocol
The AS patients included in this study had all been receiv-
ing infliximab for the preceding 3 years, having participated
in the first published randomized clinical trial on this therapy
in active AS [4,5,8,9]. After the initial, placebo-controlled
phase of that trial, the patients entered open extension
phases, in which they were treated continuously with 5 mg/
kg infliximab every 6 weeks. At the end of the third year of
the study (defined as time point (TP)1), all the patients (n =
43) had the opportunity to continue for another extension
phase. Only one patient discontinued, because of a side
effect. All the others (n = 42) were included in the present
extension. In accordance with the study protocol, they gave
their informed consent and agreed to discontinuation of the
infliximab treatment.
The study was approved by the local ethics committee of
each site that participated in this multicenter trial.
Thereafter they were visited regularly at 6-week intervals for
assessment of their clinical disease state and the time to
relapse (TtR). Relapse was defined as a Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) value ≥ 4
[10]and a physician's global assessment score ≥ 4 accord-
ing to the recommendations of the Assessments in Anky-
losing Spondylitis (ASAS) working group [11]. Patients
were invited to present to the centers between the 6-week
intervals at any time if symptoms suggestive of relapse or
other problems occurred, and if they did, their clinical
symptoms were documented accordingly. In cases of
relapse, the patients were reinfused with infliximab at 5 mg/
kg (TP2) and were then followed up for 12 weeks after the
first reinfusion. All the patients were offered an opportunity
to enter the next phase of the trial, for another 2 years.
Assessment of the individual disease course after 
discontinuation
Clinical data were assessed at TP1 and TP2 by use of the
standard indicators: disease activity as measured by the
BASDAI, C-reactive protein (CRP), and erythrocyte sedi-
mentation rate (ESR). Function was assessed according to
the Bath Ankylosing Spondylitis Functional Index (BASFI)
[12], and mobility was assessed according to the Bath AS
Metrology Index (BASMI) [13]. The patient's global assess-
ment score, the physician's global assessment score, and
the numerical rating scale for pain (NRS-P) were each
assessed on a numerical rating scale ranging from 0 to 10.
Statistical analysis
The correlation of the data at the two time points was cal-
culated using Pearson's correlation coefficient. The clinical
and laboratory data for the patients who experienced a
relapse (that is, at TP2) were compared with the data found
at TP1.
A Kaplan-Meier survival analysis was used to calculate the
probability of a relapse, with duration of response as sur-
vival time and relapse as a binomial covariate for the end
point. A Cox proportional hazards regression analysis was
used to identify possible predictors of flare.
In addition, patients were stratified both according to their
BASDAI values at the time of discontinuation, using a cutoff
value of 3 at TP1, and also according to the ASAS working
group criteria for partial remission at TP1 [14]. Partial
remission was defined as a score ≤ 2 (on a scale of 0 to 10)
in each of the four ASAS 20% domains, according to the
ASAS criteria. The TtR in these groups was compared
using a log-rank test. All statistical tests were two-tailed.
Results
Baseline findings, at discontinuation of anti-TNF therapy
Table 1 summarizes the mean ages of the patients, their
scores on the various measures of AS, the mean ESR, and
the mean CRP concentration at TP1, when anti-TNF treat-
ment was discontinued.
The BASDAI values at TP1 were >3 for 13 (31%) of the 42
patients and >4 for 8 (19%) of the 42. The latter were still
receiving treatment, because they had experienced a signif-
icant decrease of their BASDAI values, of about 30% com-
pared with their baseline value at the start of the study
(mean BASDAI 7.4 at baseline versus 5.3 at TP1) and
reported definite subjective improvement. At TP 1, 14
(33%) of the 42 patients were in partial remission [14].
Duration of response after discontinuation
By 3 weeks after the last patient reached TP2, 41 of the 42
patients were being reinfused because of relapse (Fig. 1).
Although the first patient reached TP2 after 7 weeks, it took
the last patient more than 52 weeks. However, most
patients (64%) experienced a flare between week 12 (10/
42 patients; 23.8%) and week 24 (37/42 patients; 88.1%).
The mean time between TP 1 and TP 2 was 17.5 weeks (±
7.9 weeks, range 7 to 45) and the median time was 15
weeks.
Means and changes of the assessed parameters after 
discontinuation of treatment
Between TP1 and TP2, the mean increase of the BASDAI
was 3.6 (± 1.7), the mean increase of CRP was 17.6 mg/l
(± 23.4 mg/l), and the mean increase of the ESR was 21.0
mm/hour (± 29.7 mm/hour), (all P < 0.001 in comparison
of TP1 with TP2). All changes between the two time points
were statistically significant (Table 1).
Correlations between the individual parameters
The changes in the BASDAI correlated well with the
changes in the BASMI (r = 0.35, P = 0.03) and the BASFI
(r = 0.79, P < 0.001). The changes in these three indexes
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assessment score (r = 0.81, r = 0.32, and r = 0.74, respec-
tively; all P < 0.05) and in the physician's global assess-
ment score (r = 0.49, r = 0.39, and r = 0.46, respectively;
all P < 0.05). The change in the NRS-P correlated well with
the change in all clinical findings but not with the laboratory
values (data not shown). The TtR was not correlated with
any clinical parameter.
Correlations between clinical remission and disease 
activity and response to discontinuation of treatment
Patients in partial remission at TP1 (n = 15) had a longer
duration of response than patients who did not fulfill remis-
sion criteria (P = 0.059). The mean TtR was 21.3 weeks
(95% confidence interval (CI), 15.5 to 27.2 weeks) for
patients in remission but only 15.4 weeks (12.7 to 18.1) for
the other group (Fig. 2a).
Similarly, in the analysis of the disease status at TP1, there
was also a difference between the patients with low (BAS-
DAI <3) and high (BASDAI ≥ 3) disease activity (Fig. 2b; P
= 0.039); the mean TtR of the patients with high disease
activity was 14.8 weeks (CI 10.0 to 19.6) and the mean TtR
of the patients with low disease activity was 18.9 (CI 15.4
to 22.4). This result was confirmed by a Cox regression
analysis. A higher BASDAI, an elevated CRP, older age,
and a longer disease duration were associated with a
shorter TtR. Three of seven patients with a CRP >6 mg/l at
the end of year 3 (TP1) had already experienced a relapse
by 12 weeks, and the remaining four patients, by 16 weeks
(Fig. 2c; P = 0.009). The cumulative probability of relapse
was less in patients with low CRP levels (20% by week 12
and 60% by week 16, respectively) than in patients with
elevated CRP levels (43% by week 12 and 100% by week
16, respectively).
Response to retreatment
All 41 patients who were reinfused responded well to the
restart of therapy with infliximab. They showed a clear
improvement of signs and symptoms and reached a dis-
ease state similar to that before the treatment was discon-
tinued. The main inclusion and outcome parameter, the
BASDAI, had improved from 6.1 ± 1.4 at TP2 to 3.2 ± 2.6
by 6 weeks after reinfusion and to 2.9 ± 2.1 by 12 weeks
after reinfusion, respectively (both P < 0.001). All other
parameters improved similarly well in comparison with TP2
(not shown).
There was no adverse event and no other safety concern
after resumption of infliximab therapy.
Discussion
Infliximab has proven clinical efficacy in patients with active
AS, which is associated with definite improvement of dis-
ease activity in both the short and the long term, for up to 3
years [5,6]. Our study is the first to examine the clinical
response to discontinuation of long-term infliximab therapy
Table 1
Clinical and laboratory findings for 42 patients with ankylosing spondylitis treated with infliximab
Finding BASDAI BASMI BASFI PatGA PhysGA NRS-P ESR (mm/h) CRP (mg/l)
At time point 1a
Mean ± SD 2.5 ± 1.8** 2.7 ± 2.0* 2.9 ± 2.4** 2.6 ± 1.5** 2.6 ± 2.1** 2.6 ± 2.1** 10.5 ± 7.3** 3.1 ± 4.2**
Median 2.4 2.0 2.5 4.0 2.0 2.0 8.0 1.1
Range 0.0 - 6.8 0.0 - 7.0 0.0 - 8.3 0.0 - 8.0 0.0 - 4.0 0.0 - 7.0 2.0 - 32.0 0.0 - 19.0
At time point 2a
Mean ± SD 6.1 ± 1.4** 3.2 ± 2.2* 5.8 ± 1.8** 6.9 ± 2.1** 7.0 ± 1.5** 7.1 ± 1.7** 31.5 ± 29.7** 20.7 ± 23.7**
Median 6.2 3.0 5.7 7.0 7.0 7.0 23.0 14.0
Range 4.0 - 9.2 0.0 - 9.0 1.2 - 9.1 4.0 - 10.0 4.0 - 10.0 0.0 - 10.0 4.0 - 150.0 0.3 - 126.0
Change between time points 1 and 2
Mean ± SD 3.6 ± 1.7 0.5 ± 1.5 2.9 ± 2.0 4.3 ± 1.9 4.4 ± 1.8 4.5 ± 2.2 21.0 ± 29.7 17.6 ± 23.4
Median 3.6 0.5 2.5 4.0 4.0 4.0 12.0 11.5
Range -1.2 - 6.7 -4.0 - 3.0 -0.5 - 7.8 -2.0 - 8.0 -2.0 - 8.0 -1.0 - 8.0 -6.0 - 146.0 -6.3 - 123.0
aTime point 1 is the time point at which infliximab treatment was discontinued; time point 2 is that when retreatment began. *P < 0.05, **P < 
0.001, when means at time points 1 and 2 are compared. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing 
Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
NRS-P, numerical rating scale for pain; PatGA, patient's global assessment; PhysGA, physician's global assessment; SD, standard deviation.
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made.
First, we found that discontinuation of long-term therapy
with infliximab in patients with AS leads to a clinical relapse
of the disease, with deterioration of signs and symptoms,
after several weeks to months. This indicates that the
majority of patients may, rather, need continuous anti-TNF
therapy.
Another finding is that even though there were relapses
eventually, in many patients the low disease activity at dis-
continuation of therapy persisted for some weeks after dis-
continuation, although only one patient was in ongoing
remission for more than 1 year. The mean duration of ongo-
ing response was almost 4 months. Since the time of per-
sistent clinical efficacy of infliximab after discontinuation
varied widely between patients, the optimal dose and the
optimal infusion interval for infliximab is also likely to be dif-
ferent from patient to patient. The best dosage probably
needs to be defined individually.
We also found that there seem to be predictive factors for
the duration of clinical improvement after discontinuation of
infliximab therapy in AS patients. The data suggest that clin-
ical improvement persists longer when a state of partial
remission, low disease activity, and low CRP levels are
present at the time of discontinuation. Thus, the outcome
after discontinuation can be partly predicted.
These conclusions are complementary to those predictive
of major response that have been reported recently [15].
Overall, it seems that patients who may be candidates for
Figure 1
Cumulative percentages (confidence intervals) of retreatment after dis-continuation of infliximab in patients treated for ankylosing spondylitis
continuation of infliximab in patients treated for ankylosing spondylitis. 
Retreatment depended on the duration of response to the initial treat-
ment. Of the 42 patients, 10 had to be retreated within 12 weeks after 
discontinuation of infliximab infusions, 37 within 24 weeks, and 38 
within 36 weeks. By week 48, 1 of the 42 patients had not needed 
retreatment and 41 were again receiving infliximab.
Figure 2
Kaplan-Meier analysis of time to relapse in AS patients after discontinu-ation of infliximab treatment
ation of infliximab treatment. (a) Cumulative probability of relapse ana-
lyzed according to state of remission as measured by ASAS partial 
remission criteria at TP1. Patients were (bold line) or were not (thin line) 
in partial remission at TP1. (b) Cumulative probability of relapse 
according to state of disease activity at TP1 as indicated by a BASDAI 
≥ 3 (high disease activity) (thin line) or <3 (low disease activity) (bold 
line). (c) Cumulative probability of relapse according to state of disease 
activity at TP1 as indicated by a CRP ≤ 6 mg/l (bold line; low disease 
activity) or >6 mg/l (thin line; increased disease activity). AS, ankylosing 
spondylitis; ASAS, Assessments in Ankylosing Spondylitis [working 
group]; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
CRP, C-reactive protein; pts., patients; TP1, time point 1 (when inflixi-
mab treatment was discontinued).
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of infliximab therapy have a better outcome if this decision
is made while the patients are in a state of low disease
activity. Such patients are more likely to have ongoing ben-
efit from previous therapy for several more months.
The favorable response after retreatment argues against an
important role of formation of antibodies to infliximab (ATI)
in these patients. This response is probably due to the
preselection of the patients by the previous 3 years of per-
sistent high-dose therapy with infliximab, which clearly dif-
fers from other approaches [16].
Discontinuation of infliximab may become necessary in var-
ious patients: those who are in remission for long periods
and simply want to test the remission; those who want to
become pregnant and wish to exclude the risk of medica-
tion toxicity (although there is no indication that infliximab
may be harmful); those with more severe or repetitive infec-
tion(s); and those who have to undergo surgery (although
there is no reason to think that ongoing infliximab therapy
may be harmful, good data are lacking).
Another finding of our study is that discontinuation of inflix-
imab therapy seems justified, since we found that retreat-
ment with infliximab was safe, resulting in a good clinical
response, similar to that before discontinuation. There was
no loss of efficacy and no need for an increased dose after
the new start of infliximab therapy. Thus, if for any reason
discontinuation of anti-TNF therapy is considered neces-
sary, that seems possible with no major problems regarding
efficacy and safety. This may have definite implications for
daily practice, since discontinuation of therapy at certain
intervals, such as after 1 or 2 years of therapy, may become
a standard approach. Payers and patients may want to
make sure that further anti-TNF therapy is needed. An inter-
mittent cessation of anti-TNF therapy may be considered in
the case of patients who respond well to infliximab therapy
for longer periods of time. Since it is unknown how long the
patients should receive anti-TNF therapy, it is unclear how
to deal with this uncertainty in clinical practice. One possi-
ble approach would be to check from time to time whether
the disease is still active or has become active again after
initial improvement due to infliximab therapy. Another pos-
sibility would be to slowly extend the intervals between infu-
sions. This approach would obviously have important
economic implications.
However, we think that no clear recommendation for such
an approach can be given in the light of present knowledge.
More work is needed to confirm our findings and further
studies are required to better clarify these issues.
The decision to use a BASDAI cutoff score of 4 is based
on the ASAS recommendations. The decision to use a cut-
off score of 3 to indicate low disease activity is, at the
moment, arbitrary but may serve as a basis for further dis-
cussion. It will be especially interesting to learn from the
patients whether a score of 3 comes closer to indicating an
acceptable state.
Conclusion
Therapy with infliximab has definite long-term clinical effi-
cacy and safety in patients with AS. Patients who discon-
tinue therapy are likely to have a clinical relapse within
several weeks to months. Therefore, continuous therapy
seems to be necessary for most patients with AS. Impor-
tantly, however, we found that retreatment is safe and the
clinical efficacy is as good as that before discontinuation.
Patients in partial remission or with low disease activity
have a longer duration of response after discontinuation
than patients with higher disease activity. Overall, anti-TNF
therapy is a major step forward in the treatment of patients
with AS.
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